Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded to “Buy” at ValuEngine

ValuEngine upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS) from a hold rating to a buy rating in a research note issued to investors on Wednesday, ValuEngine reports.

SYRS has been the topic of several other reports. BidaskClub raised shares of Syros Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, July 12th. Roth Capital assumed coverage on shares of Syros Pharmaceuticals in a research note on Friday, July 12th. They set a buy rating and a $17.00 price target on the stock. Finally, Zacks Investment Research raised shares of Syros Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $16.03.

NASDAQ:SYRS traded down $0.06 during mid-day trading on Wednesday, hitting $11.59. 132,500 shares of the company’s stock traded hands, compared to its average volume of 177,555. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.11 and a current ratio of 8.11. The firm’s 50 day simple moving average is $9.49 and its 200 day simple moving average is $7.88. Syros Pharmaceuticals has a 1 year low of $5.17 and a 1 year high of $13.16. The company has a market cap of $426.50 million, a PE ratio of -6.07 and a beta of 1.62.



Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, August 1st. The company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.06). Syros Pharmaceuticals had a negative net margin of 3,137.55% and a negative return on equity of 79.79%. The business had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.42 million. On average, research analysts expect that Syros Pharmaceuticals will post -1.94 earnings per share for the current fiscal year.

In related news, Director Richard A. Young sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $10.00, for a total value of $250,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $7.77, for a total transaction of $489,510.00. The disclosure for this sale can be found here. 14.80% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in SYRS. Bank of America Corp DE boosted its position in shares of Syros Pharmaceuticals by 205.9% in the fourth quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after acquiring an additional 11,711 shares during the last quarter. BNP Paribas Arbitrage SA acquired a new stake in shares of Syros Pharmaceuticals in the first quarter worth approximately $48,000. Wedge Capital Management L L P NC boosted its position in shares of Syros Pharmaceuticals by 35.7% in the first quarter. Wedge Capital Management L L P NC now owns 83,333 shares of the company’s stock worth $762,000 after acquiring an additional 21,944 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Syros Pharmaceuticals in the first quarter worth approximately $6,256,000. Finally, ARK Investment Management LLC boosted its position in shares of Syros Pharmaceuticals by 21.6% in the first quarter. ARK Investment Management LLC now owns 2,992,700 shares of the company’s stock worth $27,353,000 after acquiring an additional 532,079 shares during the last quarter. 82.08% of the stock is currently owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Further Reading: What is a Stop Order?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.